Chronic Myeloid Leukemia Coverage from Every Angle

Susanne Saussele, Prof Dr, on Bosutinib in Patients With Chronic Phase CML

Posted: Wednesday, June 24, 2020

Susanne Saussele, Prof Dr, of the Medical Faculty Mannheim, University of Heidelberg, discusses findings from the BYOND study, which showed a high response rate with bosutinib in patients with chronic phase chronic myeloid leukemia who were intolerant to prior tyrosine kinase inhibitor therapy and whose disease was Philadelphia chromosome–positive.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.